Medical Oncology

Prof. Dr. Bülent Karabulut

Doctor and researcher Acıbadem Kent Hastanesi (İzmir) İzmir
Colorectal NeoplasmsBreast NeoplasmsProstatic NeoplasmsOvarian NeoplasmsAdenocarcinomaRectal NeoplasmsGastrointestinal NeoplasmsColonic NeoplasmsObesityNeoplasmsStomach NeoplasmsPancreatic NeoplasmsNeoplasms, Hormone-DependentCarcinoma, Renal CellKidney NeoplasmsHypertensionHematologic DiseasesLiver NeoplasmsBone NeoplasmsCystadenocarcinoma, SerousCarcinoma, Small Cell

Is this your profile? Claim it and verify your details.

Claim profile

The CV details on this page were translated automatically from the language of the source. See the original

Person ↔ Disease

Which diseases does this doctor work on?

From source
  • Colorectal Neoplasms 15 publications
    Source: OpenAlex / PubMed MeSHView publications
  • Breast Neoplasms 14 publications
  • Prostatic Neoplasms 13 publications
  • Ovarian Neoplasms 10 publications
  • Adenocarcinoma 6 publications
  • Rectal Neoplasms 5 publications
  • Gastrointestinal Neoplasms 4 publications
  • Colonic Neoplasms 4 publications
  • Obesity 4 publications
  • Neoplasms 4 publications
  • Stomach Neoplasms 3 publications
  • Pancreatic Neoplasms 3 publications
  • Neoplasms, Hormone-Dependent 3 publications
  • Carcinoma, Renal Cell 2 publications
  • Kidney Neoplasms 2 publications
  • Hypertension 2 publications
  • Hematologic Diseases 2 publications
  • Liver Neoplasms 2 publications
  • Bone Neoplasms 2 publications
  • Cystadenocarcinoma, Serous 2 publications
  • Carcinoma, Small Cell 2 publications

Person ↔ Disease

Which topics does this doctor work on?

From source

Medical areas of interest stated by the doctor on the institution profile. Source: acibadem.com.tr.

  • Ovarian cancer
  • Gynaecological tumours and cancers (uterine, cervical, ovarian cancer, etc.)
  • Pancreatic cancer
  • Oesophageal cancer
  • Gastric cancer
  • Bladder cancer
  • Breast cancer
  • Gallbladder and biliary tract cancers
  • Peritoneal cancer
  • Liver cancer
  • Endometrial cancer
  • Kidney cancer
  • Lung and pleural cancers (mesothelioma) and other thoracic cancers
  • Head and neck cancers
  • Colorectal cancer (colon and rectal cancer)
  • Gallbladder cancer
  • Lung cancer
  • Colon (large bowel) cancer

CV

Education and experience

From source

Experience

  • 2023Acıbadem Healthcare Groupacibadem.com.tr
  • 1997Research in the medical oncology cell research laboratory, Ege University Faculty of Medicineacibadem.com.tr
  • ExperienceKent Hastanesi (private hospital), Kent Oncology Centre: General Coordinator and Medical Oncologistacibadem.com.tr

Education

  • 2011Professorshipacibadem.com.tr
  • 2006Associate Professorshipacibadem.com.tr
  • 2001Ege University Faculty of Medicine, Medical Oncology (subspecialty)acibadem.com.tr
  • 1999Ege University Faculty of Medicine, Internal Medicine (specialty training)acibadem.com.tr
  • 1993Ege University Faculty of Medicine (medical degree)acibadem.com.tr

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyMedical Oncologyacibadem.com.trFrom source
  • InstitutionAcıbadem Kent Hastanesi (İzmir)acibadem.com.trFrom source
  • Area of workColorectal NeoplasmsExtracted from 15 publications · Model version —From source
  • Publications196 publicationsOpenAlex, ORCIDFrom source
  • ORCID0000-0002-1949-8334ORCIDFrom source
  • Last synchronised4 November 2026 20:48https://www.acibadem.com.tr/doktor/bulent-karabulut/acibadem.com.tr

Scientific work

Publications on Colorectal Neoplasms

196 publications
  1. Real-world practices in RAS wild-type metastatic colorectal cancer patients treated with targeted agents in the first-line a nationwide onco-colon Turkey registry

    Anadolu Kliniği Tıp Bilimleri Dergisi, 2026

    DOI 10.21673/anadoluklin.1675424 Open-access full textSource: OpenAlex

  2. Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study

    Cancers, 2026

    DOI 10.3390/cancers18121979 PMID 42352512 Open-access full textSource: OpenAlex

  3. Prognostic and Treatment-Specific Predictive Implications of HER2 Expression in RAS Wild-Type Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Study

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15103979 PMID 42194940 Open-access full textSource: OpenAlex

  4. Real-World Efficacy and Safety of Frontline Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Study and Review of the Literature

    Clinical Genitourinary Cancer, 2026

    DOI 10.1016/j.clgc.2026.102594 PMID 42349378 Source: OpenAlex

  5. Clinical Characteristics, Treatment Patterns, and Survival Outcomes of Right-Sided RAS/RAF Wild-Type Metastatic Colorectal Cancer: A Real-World Multicenter Cohort Study

    Clinics and Practice, 2026

    DOI 10.3390/clinpract16090158 PMID 42783081 Open-access full textSource: OpenAlex

  6. Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study

    Current Oncology, 2026

    DOI 10.3390/curroncol33060365 PMID 42346265 Open-access full textSource: OpenAlex

  7. Real-World Survival Outcomes Following Metastasectomy in RAS Wild-Type mCRC: Insights from a Multicentre National Cohort Study

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15020467 PMID 41598406 Open-access full textSource: ORCID

  8. Association Between Preoperative Albumin-to-Globulin Ratio (AGR) and Recurrence-Free Survival in High-Risk Resected Cutaneous Melanoma

    Eurasian Journal of Medical Investigation, 2026

    DOI 10.14744/ejmi.2612540 Source: ORCID

  9. Impact of oral nutritional support adherence on muscle strength, body composition, and general health status in gastrointestinal cancer patients: ONMUS study

    Nutrition, 2026

    DOI 10.1016/j.nut.2025.113029 PMID 41455457 1 citation (Europe PMC) Source: ORCID

  10. Evaluation of Olaparib Efficacy Following CDK4/6 Inhibitor Therapy in BRCA-Mutated, Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Turkish Oncology Group (TOG) Study

    Targeted Oncology, 2026

    DOI 10.1007/s11523-026-01261-w PMID 42907609 Source: OpenAlex

View all 196 publications